Literature DB >> 17542985

Increased Akt and phosphorylated Akt expression are associated with malignant biological features of prostate cancer in Japanese men.

Yousuke Shimizu1, Takehiko Segawa, Takahiro Inoue, Taizo Shiraishi, Toru Yoshida, Yoshinobu Toda, Tomomi Yamada, Naoko Kinukawa, Naoki Terada, Takashi Kobayashi, Hidefumi Kinoshita, Toshiyuki Kamoto, Eijiro Nakamura, Osamu Ogawa.   

Abstract

OBJECTIVE: To investigate the relationship between the expression of Akt (a serine/threonine kinase that plays a central role in tumorigenesis), phosphorylated Akt (p-Akt), prostate cancer tumour grade, androgen receptor (AR)-staining score, and Ki67 labelling index (LI) in Japanese men. PATIENTS,
MATERIALS AND METHODS: The expression and activation of the cell survival protein Akt was analysed by immunohistochemical staining of paraffin-embedded tissue microarray sections of prostate carcinoma taken from 52 Japanese men who under radical prostatectomy. The correlation between the expression of Akt and p-Akt, and their relationship to primary Gleason grade, AR expression and Ki-67 LI was investigated.
RESULTS: The expression of Akt and p-Akt were positively related to primary Gleason grade (Fisher's exact test, P = 0.002 and P = 0.032, respectively). Both AR-staining score and Ki67 LI were were positively related to the expression of Akt (both P < 0.001) and p-Akt (P < 0.001 and P = 0.008, respectively). There was a significant positive correlation between the expression of Akt and p-Akt (Spearman's correlation, r = 0.644, P < 0.001).
CONCLUSIONS: Increased expression of both Akt and p-Akt were associated with higher tumour grade as well as a higher AR-staining score and Ki67 LI. These data indicate that Akt and p-Akt might be molecular markers for detecting malignant biological features of prostate cancer in the Japanese population.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17542985     DOI: 10.1111/j.1464-410X.2007.07014.x

Source DB:  PubMed          Journal:  BJU Int        ISSN: 1464-4096            Impact factor:   5.588


  16 in total

1.  Multi-institutional validation of the prognostic value of Ki-67 labeling index in patients treated with radical prostatectomy.

Authors:  Romain Mathieu; Shahrokh F Shariat; Christian Seitz; Pierre I Karakiewicz; Harun Fajkovic; Maxine Sun; Yair Lotan; Douglas S Scherr; Ashutosh Tewari; Francesco Montorsi; Alberto Briganti; Morgan Rouprêt; Ilaria Lucca; Vitaly Margulis; Michael Rink; Luis A Kluth; Malte Rieken; Alexander Bachman; Evanguelos Xylinas; Brian D Robinson; Karim Bensalah; Markus Margreiter
Journal:  World J Urol       Date:  2014-10-26       Impact factor: 4.226

2.  Measuring PI3K Activation: Clinicopathologic, Immunohistochemical, and RNA Expression Analysis in Prostate Cancer.

Authors:  Neil E Martin; Travis Gerke; Jennifer A Sinnott; Edward C Stack; Ove Andrén; Swen-Olof Andersson; Jan-Erik Johansson; Michelangelo Fiorentino; Stephen Finn; Giuseppe Fedele; Meir Stampfer; Philip W Kantoff; Lorelei A Mucci; Massimo Loda
Journal:  Mol Cancer Res       Date:  2015-06-29       Impact factor: 5.852

3.  Impact of combined HDAC and mTOR inhibition on adhesion, migration and invasion of prostate cancer cells.

Authors:  Steffen Wedel; Lukasz Hudak; Jens-Michael Seibel; Jasmina Makarević; Eva Juengel; Igor Tsaur; Christoph Wiesner; Axel Haferkamp; Roman A Blaheta
Journal:  Clin Exp Metastasis       Date:  2011-03-31       Impact factor: 5.150

4.  Prognostic value of Ki67 in localized prostate carcinoma: a multi-institutional study of >1000 prostatectomies.

Authors:  M S Tretiakova; W Wei; H D Boyer; L F Newcomb; S Hawley; H Auman; F Vakar-Lopez; J K McKenney; L Fazli; J Simko; D A Troyer; A Hurtado-Coll; I M Thompson; P R Carroll; W J Ellis; M E Gleave; P S Nelson; D W Lin; L D True; Z Feng; J D Brooks
Journal:  Prostate Cancer Prostatic Dis       Date:  2016-05-03       Impact factor: 5.554

Review 5.  Targeting prostate cancer based on signal transduction and cell cycle pathways.

Authors:  John T Lee; Brian D Lehmann; David M Terrian; William H Chappell; Franca Stivala; Massimo Libra; Alberto M Martelli; Linda S Steelman; James A McCubrey
Journal:  Cell Cycle       Date:  2008-06-16       Impact factor: 4.534

6.  Prediction of prostate cancer recurrence using magnetic resonance imaging and molecular profiles.

Authors:  Amita Shukla-Dave; Hedvig Hricak; Nicole Ishill; Chaya S Moskowitz; Marija Drobnjak; Victor E Reuter; Kristen L Zakian; Peter T Scardino; Carlos Cordon-Cardo
Journal:  Clin Cancer Res       Date:  2009-05-12       Impact factor: 12.531

7.  Correlation of MR imaging and MR spectroscopic imaging findings with Ki-67, phospho-Akt, and androgen receptor expression in prostate cancer.

Authors:  Amita Shukla-Dave; Hedvig Hricak; Nicole M Ishill; Chaya S Moskowitz; Marija Drobnjak; Victor E Reuter; Kristen L Zakian; Peter T Scardino; Carlos Cordon-Cardo
Journal:  Radiology       Date:  2009-03       Impact factor: 11.105

8.  Impact of circulating cholesterol levels on growth and intratumoral androgen concentration of prostate tumors.

Authors:  Elahe A Mostaghel; Keith R Solomon; Kristine Pelton; Michael R Freeman; R Bruce Montgomery
Journal:  PLoS One       Date:  2012-01-18       Impact factor: 3.240

Review 9.  The role of treatment modality on the utility of predictive tissue biomarkers in clinical prostate cancer: a systematic review.

Authors:  Naveen Kachroo; Vincent J Gnanapragasam
Journal:  J Cancer Res Clin Oncol       Date:  2012-11-28       Impact factor: 4.553

10.  Caffeic Acid phenethyl ester as a potential treatment for advanced prostate cancer targeting akt signaling.

Authors:  Hui-Ping Lin; Ching-Yu Lin; Chun-Chieh Liu; Liang-Cheng Su; Chieh Huo; Ying-Yu Kuo; Jen-Chih Tseng; Jong-Ming Hsu; Chi-Kuan Chen; Chih-Pin Chuu
Journal:  Int J Mol Sci       Date:  2013-03-06       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.